Globus Medical (GMED, Financials) agreed to acquire Nevro Corp. (NVRO, Financials) in an all-cash transaction valued at approximately $250 million.

• Warning! GuruFocus has detected 7 Warning Signs with GMED.

Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% premium over its 90-day volume-weighted average price and a 17% premium over its closing price on Feb. 5, 2025.

Subject to shareholder and legal clearances, the transactionwhich both firms' boards have approved generallyis likely to occur in late Q2 2025. Globus Medical said the purchase would increase its portfolio of musculoskeletal technologies, therefore enhancing its position in neuromodulation and chronic pain management. Nevro, with its HFXTM spinal cord stimulation device, should gain from Globus' operational scope and worldwide infrastructure.

While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year over year. Globus anticipates $2.80 billion to $2.90 billion in sales after the closing of the purchase, with non-GAAP earnings per share ranging from $3.10 to $3.40.

Nevro shareholder approval, regulatory clearance, and usual closing conditions govern the deal. Late Q2 2025 is projected to see closing. Nevro has also said that, upon publishing its full-year 2024 results on March 4, it would not host an earnings call or provide a 2025 financial outlook owing to the pending deal.